Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.
